Claims for Patent: 10,082,510

Summary for Patent: 10,082,510

Title:	SRC-2 use as metabolic biomarker for diagnosis and treatment of metastatic prostate cancer
Abstract:	Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.
Inventor(s):	O\'Malley; Bert W. (Houston, TX), Dasgupta; Subhamoy (Houston, TX), Mitsiades; Nicholas (Boston, MA), Sreekumar; Arun (Sugar Land, TX), Mcguire; Sean E. (Bellaire, TX)
Assignee:	Baylor College of Medicine (Houston, TX)
Application Number:	15/309,143
Patent Claims:	1. A method of treating an individual for metastatic prostate cancer, or preventing or reducing metastatic cancer in the individual, comprising the step of providing a therapeutically effective amount of treatment for the metastatic prostate cancer when a sample from the individual indicates that there is an elevated level of SRC-2 in cells from the sample, wherein the level is measured by the following: administering .sup.13C-labeled glutamine to the individual; obtaining a sample from the individual, wherein the sample is suspected of comprising or known to comprise cancer cells; and one of the following: 1) measuring the level of citrate m+5 or the ratio of citrate m+5/citrate m+4 from the cells after the administering step, wherein when the level of citrate m+5 or the ratio is elevated compared to a reference level measured before administration, the individual is in need of treatment, prevention, or the reduction of metastatic cancer, or 2) measuring after the administering step for the presence of .sup.13C in one or more of palmitic acid, stearic acid, palmitoleic acid, oleic acid, and myristic acid, wherein when .sup.13C is present, the individual is in need of treatment, prevention, or the reduction of metastatic cancer, or 3) measuring the level of citrate m+1 from the cells after the administering step, wherein when the level of citrate m+1 is elevated compared to a reference level measured before administration, the individual is in need of treatment, prevention, or the reduction of metastatic prostate cancer. 2. The method of claim 1, wherein the sample is urine, serum, blood, tissue biopsy, prostatic fluid, semen, breath, secretions, or a mixture thereof. 3. The method of claim 1, wherein the treatment comprises one or more agents that inhibit the level and/or activity of SRC-2. 4. The method of claim 3, wherein the agents comprise one or more functionally active derivatives of bufalin. 5. The method of claim 1, wherein the treatment comprises chemotherapy, hormone therapy, immunotherapy, radiation, surgery, or a combination thereof. 6. The method of claim 1, further comprising the step of administering one or more glutamine analogs to the individual. 7. The method of claim 6, wherein the one or more glutamine analogs is selected from the group consisting of 6-diazo-5-oxo-L-norleucine (DON), L-g-glutamyl-p-nitroanilide (GPNA), and a mixture thereof. 8. The method of claim 1, wherein the treatment comprises a LHRH analog, antiandrogen, or a combination thereof. 9. The method of claim 8 wherein the LHRH analog is leuprolide, goserelin, triptorelin, histrelin, or a combination thereof. 10. The method of claim 8 wherein the antiandrogen is flutamide, bicalutamide, nilutamide, or a combination thereof. 11. The method of claim 1, wherein the treatment comprises abiraterone, MDV3100, Ipilimumab, bisphosphonate, leuprolide, or a combination thereof. 12. The method of claim 1 wherein citrate m+5 is measured after administration of [U-.sup.13C]glutamine. 13. The method of claim 1 wherein citrate m+1 is measured after administration of [1-.sup.13C]glutamine.

Details for Patent 10,082,510

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	03/25/2011		2035-01-30